About Nuvalent
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.
Leadership at Nuvalent
The team at the top of the org chart.
James Porter
CEO
194 reports
Christopher Turner
Chief Medical Officer
62 reports
Jason Waters
Senior Vice President, Head of Commercial
49 reports
Henry Pelish
Chief Scientific Officer
19 reports
Benjamin Lane
SVP, Technical Operations
16 reports
Alex Balcom
Chief Financial Officer
14 reports
Matthew Metivier
VP, Human Resources
10 reports
Jeffrey Lee
Vice President, IT
8 reports
Jessie Lin
Senior Vice President, Corporate Strategy & Portfolio Management
4 reports
Board
Anna Protopapas
Director
Andrew A. F. Hack
Director
Joseph Pearlberg
Director
Sapna Srivastava
Independent Board Member
Michael Meyers
Independent Board Member
Pasi Jänne
Scientific Advisor